gip/glp-1 receptor agonist drugs list What to know about the new era of GLP-1 Upcoming wave of hormone-based therapies
Description
Longwell, C
Aliment Pharmacol Ther 2023;58:395-403.ArticlePubMed 122
placebo in 120 people with overweight/obesity and chronic kidney disease (CKD) is ongoing
The primary endpoint was the percentage weight loss at six months (M6) compared to baseline
This study aimed to clarify the association between GLP-1 RA use and GI cancer risk
doi:10.3390/molecules26237306 14
